Research programme: ophthalmologic gene therapy - Adverum/Regeneron

Drug Profile

Research programme: ophthalmologic gene therapy - Adverum/Regeneron

Alternative Names: AVA 311

Latest Information Update: 08 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avalanche Biotechnologies; Regeneron Pharmaceuticals
  • Developer Adverum Biotechnologies; Regeneron Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Retinoschisis

Most Recent Events

  • 07 Mar 2017 Regeneron extends the license agreement with Adverum for additional three years
  • 24 Nov 2015 CRISPR-Cas9 genome-editing patents licensed to Regeneron Pharmaceuticals
  • 24 Nov 2015 ERS Genomics has patent protection for CRISPR-Cas9 patent portfolio in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top